Phathom Pharmaceuticals Inc. (PHAT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 Earnings Call Transcript
Phathom Pharmaceuticals Q2 Earnings Call Highlights
Phathom Pharmaceuticals NASDAQ: PHAT reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first time in its history, reaching the milestone one quarter ahead of its prior plan.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals, Inc. (PHAT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.79 per share a year ago.
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy compared to PPIs.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO, President & Director Sanjeev Narula - Chief Financial & Business Officer Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Stringer - Needham & Company, LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Phathom Pharmaceuticals' Third Quarter 2025 Earnings Results Call.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $1.32 per share a year ago.
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & Principal Accounting Officer Steven L. Basta - CEO, President & Director Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Robert Stringer - Needham & Company, LLC, Research Division Jyhhaw Liu - Evercore ISI Institutional Equities, Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Matthew Coleman Caufield - H.C.
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.25 per share a year ago.
